Second-line therapies for rheumatoid arthritis include drugs targeting the interleukin-6 receptor. Olokizumab, an antibody that binds directly to interleukin-6, might offer another treatment option. New research findings are summarized in a short video.
This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .
Quick Take Free Preview